research Controversies: Is Finasteride Safety Data Adequately Reported in Published Trials?
This article discusses adverse event reporting in clinical trials of finasteride for androgenic alopecia and reports no new clinical findings.
Search
forResearch
5 / 1000+ resultsresearch Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.
research Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.
research AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
This study observed that while all DMARD regimens had similar safety profiles, the leflunomide group experienced the most serious side effects leading to therapy discontinuation.
research Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.
Community Join
5 / 956 resultscommunity PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Has anyone seen the data on this 539% boost breakthrough?
Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.
community Rate my MPB Genetics: Can I run Primobolan/Masteron? (Detailed MyHeritage DNA Data Included)
The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.
community BREAKTHROUGH: I’m a radiochemist and discovered a radioactive isotope scalp serum that OUTPERFORMS Minoxidil and 5-AR inhibitors! (Lab Data Inside)
A satirical post where someone claims to have developed a radioactive isotope scalp serum using Polonium-210 that outperforms Minoxidil and finasteride for hair regrowth. The serum reportedly stimulates DNA repair in hair follicles, leading to significant hair density increase, but the post is met with skepticism and concerns about safety.
community Does RU58841 potentially cause cancer?
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
Learn
10 / 801 results- What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth? No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.
- Is KY19382 safe to use long-term, or is it still considered experimental? KY19382 is still considered experimental and lacks long-term safety data.
- GHK-Cu: Does it have side effects or is it completely safe? For topical cosmetic use, the small laboratory evidence base found GHK-Cu non-irritating, and reported reactions are local and uncommon; for injected or oral use there is effectively no human safety data, and the FDA lists GHK-Cu among bulk substances that may present significant safety risks in compounding.
- Is Fluridil only for men with androgenetic alopecia, or can women use it too? The only published clinical study of fluridil enrolled 43 men, so its use in women is untested rather than established; women considering it should talk to a doctor, and it is not advised in pregnancy or breastfeeding because no reproductive-safety data exists.
- Is HMI-115 considered a safe option, or does it have strong side effects? HMI-115 is an experimental injected antibody, not a hormone blocker: the one published trial (in endometriosis) reported an acceptable 12-week tolerability profile with no treatment-related serious adverse events, and no peer-reviewed safety data exists for its use in hair loss.
learn SCUBE3
learn KY19382
learn GHK-Cu
learn Fluridil
learn HMI-115
learn GT20029
research compound made to degrade androgen receptors in scalp
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Hair Multiplication
extract, clone, and reinsert your own hair cells
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
